Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Estrogen | 55 | 2022 | 2086 | 5.250 |
Why?
|
Breast Neoplasms | 122 | 2023 | 15694 | 4.920 |
Why?
|
Receptor, ErbB-2 | 50 | 2023 | 2518 | 4.510 |
Why?
|
Drug Resistance, Neoplasm | 59 | 2022 | 5178 | 3.790 |
Why?
|
Antineoplastic Agents, Hormonal | 38 | 2022 | 840 | 3.780 |
Why?
|
Estrogen Receptor alpha | 21 | 2022 | 701 | 3.480 |
Why?
|
Tamoxifen | 35 | 2022 | 876 | 3.120 |
Why?
|
Trastuzumab | 23 | 2023 | 696 | 1.990 |
Why?
|
Quinazolines | 20 | 2023 | 923 | 1.900 |
Why?
|
Receptor Cross-Talk | 11 | 2015 | 79 | 1.390 |
Why?
|
Signal Transduction | 53 | 2022 | 11965 | 1.310 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 4 | 2022 | 65 | 1.190 |
Why?
|
Transcription Factor AP-1 | 5 | 2022 | 246 | 1.110 |
Why?
|
Estradiol | 11 | 2022 | 748 | 1.090 |
Why?
|
Neoplasms, Hormone-Dependent | 6 | 2018 | 342 | 1.080 |
Why?
|
Genes, erbB-2 | 6 | 2013 | 229 | 1.040 |
Why?
|
Estrogen Receptor Modulators | 8 | 2008 | 112 | 1.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 38 | 2022 | 8873 | 1.010 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2022 | 198 | 0.960 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2022 | 129 | 0.920 |
Why?
|
ErbB Receptors | 15 | 2020 | 2295 | 0.920 |
Why?
|
Xenograft Model Antitumor Assays | 24 | 2021 | 3821 | 0.900 |
Why?
|
Mice, Nude | 31 | 2021 | 4307 | 0.880 |
Why?
|
Cell Line, Tumor | 53 | 2022 | 14551 | 0.870 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 5 | 2023 | 521 | 0.850 |
Why?
|
Phosphatidylinositol 3-Kinases | 9 | 2017 | 1678 | 0.840 |
Why?
|
PTEN Phosphohydrolase | 4 | 2017 | 986 | 0.840 |
Why?
|
Antineoplastic Agents | 24 | 2022 | 14289 | 0.830 |
Why?
|
Estrogens | 12 | 2022 | 751 | 0.770 |
Why?
|
MCF-7 Cells | 12 | 2021 | 550 | 0.750 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2023 | 15862 | 0.740 |
Why?
|
Interferons | 1 | 2022 | 291 | 0.740 |
Why?
|
Female | 109 | 2023 | 141928 | 0.690 |
Why?
|
Cinnamates | 1 | 2018 | 27 | 0.680 |
Why?
|
Aromatase Inhibitors | 6 | 2017 | 305 | 0.640 |
Why?
|
Mice | 55 | 2022 | 34495 | 0.640 |
Why?
|
Molecular Targeted Therapy | 9 | 2020 | 2330 | 0.640 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 992 | 0.630 |
Why?
|
Cell Proliferation | 26 | 2022 | 7226 | 0.630 |
Why?
|
Humans | 135 | 2023 | 261506 | 0.590 |
Why?
|
Animals | 63 | 2022 | 59536 | 0.590 |
Why?
|
Pyridines | 2 | 2021 | 1244 | 0.570 |
Why?
|
Gene Expression Profiling | 12 | 2021 | 5159 | 0.560 |
Why?
|
Receptors, Growth Factor | 3 | 2005 | 157 | 0.540 |
Why?
|
Circulating Tumor DNA | 1 | 2018 | 235 | 0.530 |
Why?
|
Precision Medicine | 2 | 2019 | 1154 | 0.510 |
Why?
|
Neoadjuvant Therapy | 11 | 2023 | 4975 | 0.510 |
Why?
|
Piperazines | 2 | 2021 | 2101 | 0.500 |
Why?
|
Lymphocytes | 1 | 2019 | 1234 | 0.490 |
Why?
|
Antibodies, Monoclonal, Humanized | 15 | 2020 | 3251 | 0.490 |
Why?
|
Interleukin-8 | 1 | 2016 | 519 | 0.480 |
Why?
|
Growth Substances | 4 | 2004 | 300 | 0.460 |
Why?
|
Indoles | 1 | 2018 | 1009 | 0.450 |
Why?
|
Chromatin | 4 | 2022 | 942 | 0.450 |
Why?
|
Epidermal Growth Factor | 5 | 2021 | 423 | 0.440 |
Why?
|
Mucin-4 | 1 | 2012 | 18 | 0.430 |
Why?
|
Neoplastic Cells, Circulating | 4 | 2019 | 607 | 0.430 |
Why?
|
DNA, Neoplasm | 2 | 2017 | 1910 | 0.430 |
Why?
|
Estrogen Antagonists | 4 | 2022 | 184 | 0.430 |
Why?
|
Antibodies, Monoclonal | 11 | 2013 | 4367 | 0.420 |
Why?
|
Biomarkers, Tumor | 15 | 2023 | 10331 | 0.420 |
Why?
|
Transcriptome | 4 | 2016 | 1859 | 0.400 |
Why?
|
RNA, Small Interfering | 13 | 2018 | 2216 | 0.400 |
Why?
|
Mammary Neoplasms, Experimental | 5 | 2014 | 494 | 0.390 |
Why?
|
Integrin beta1 | 1 | 2011 | 126 | 0.390 |
Why?
|
Gene Amplification | 5 | 2016 | 731 | 0.380 |
Why?
|
Apoptosis | 14 | 2020 | 7591 | 0.380 |
Why?
|
Receptors, Progesterone | 5 | 2015 | 1392 | 0.370 |
Why?
|
Sirolimus | 1 | 2014 | 814 | 0.360 |
Why?
|
Oncogene Proteins | 3 | 2021 | 354 | 0.360 |
Why?
|
Neoplastic Stem Cells | 3 | 2019 | 1443 | 0.360 |
Why?
|
Prognosis | 20 | 2022 | 21713 | 0.360 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2012 | 621 | 0.340 |
Why?
|
Up-Regulation | 8 | 2016 | 2450 | 0.340 |
Why?
|
Tumor Cells, Cultured | 12 | 2021 | 5395 | 0.340 |
Why?
|
Transcription, Genetic | 8 | 2020 | 3154 | 0.330 |
Why?
|
Adaptation, Physiological | 2 | 2021 | 360 | 0.330 |
Why?
|
Estrogen Receptor beta | 3 | 2008 | 155 | 0.320 |
Why?
|
Receptors, G-Protein-Coupled | 3 | 2022 | 488 | 0.320 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2018 | 661 | 0.300 |
Why?
|
Phosphorylation | 12 | 2021 | 4804 | 0.300 |
Why?
|
Gold | 3 | 2014 | 270 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 1493 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-myc | 3 | 2020 | 810 | 0.290 |
Why?
|
Transplantation, Heterologous | 8 | 2011 | 1082 | 0.280 |
Why?
|
Protein Kinases | 4 | 2016 | 874 | 0.280 |
Why?
|
Proteome | 1 | 2010 | 561 | 0.280 |
Why?
|
Epigenesis, Genetic | 4 | 2019 | 1399 | 0.280 |
Why?
|
Gene Expression | 6 | 2020 | 3570 | 0.270 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2014 | 639 | 0.270 |
Why?
|
Fibroblasts | 5 | 2022 | 1682 | 0.270 |
Why?
|
Histone Acetyltransferases | 4 | 2020 | 411 | 0.260 |
Why?
|
Cellular Reprogramming | 2 | 2020 | 189 | 0.260 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2022 | 1216 | 0.260 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 2 | 2018 | 32 | 0.260 |
Why?
|
Genes, erbB-1 | 1 | 2005 | 101 | 0.260 |
Why?
|
Neoplasm Transplantation | 9 | 2019 | 1519 | 0.250 |
Why?
|
Nanoshells | 3 | 2014 | 43 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 4 | 2021 | 4757 | 0.240 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2020 | 1546 | 0.240 |
Why?
|
Gene Knockdown Techniques | 6 | 2018 | 1077 | 0.230 |
Why?
|
Mutation | 12 | 2019 | 15179 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-akt | 6 | 2017 | 2054 | 0.230 |
Why?
|
Oligonucleotide Array Sequence Analysis | 5 | 2016 | 2508 | 0.220 |
Why?
|
Transcription Factors | 5 | 2019 | 5270 | 0.220 |
Why?
|
Receptors, Neuropeptide Y | 1 | 2022 | 6 | 0.210 |
Why?
|
Drugs, Investigational | 1 | 2003 | 135 | 0.210 |
Why?
|
Heterografts | 3 | 2022 | 733 | 0.210 |
Why?
|
RNA Interference | 5 | 2019 | 1408 | 0.210 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 2864 | 0.210 |
Why?
|
Phototherapy | 2 | 2014 | 75 | 0.210 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2022 | 42 | 0.210 |
Why?
|
Drug Resistance | 2 | 2018 | 587 | 0.200 |
Why?
|
Triple Negative Breast Neoplasms | 3 | 2018 | 1215 | 0.200 |
Why?
|
GATA3 Transcription Factor | 2 | 2020 | 146 | 0.200 |
Why?
|
Homeodomain Proteins | 2 | 2019 | 1143 | 0.200 |
Why?
|
Membrane Proteins | 1 | 2012 | 2819 | 0.200 |
Why?
|
Intercellular Signaling Peptides and Proteins | 4 | 2014 | 650 | 0.190 |
Why?
|
F-Box Proteins | 2 | 2019 | 96 | 0.190 |
Why?
|
Cell Transformation, Neoplastic | 6 | 2014 | 2359 | 0.190 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2019 | 3890 | 0.190 |
Why?
|
Clonal Evolution | 2 | 2021 | 253 | 0.190 |
Why?
|
Carrier Proteins | 3 | 2020 | 2022 | 0.180 |
Why?
|
Carcinoma | 2 | 2015 | 2578 | 0.180 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 2 | 2021 | 245 | 0.180 |
Why?
|
Repressor Proteins | 4 | 2014 | 1664 | 0.180 |
Why?
|
Mevalonic Acid | 1 | 2019 | 34 | 0.180 |
Why?
|
Enzyme Inhibitors | 4 | 2020 | 1879 | 0.180 |
Why?
|
Blotting, Western | 7 | 2011 | 3536 | 0.180 |
Why?
|
p300-CBP Transcription Factors | 1 | 2020 | 110 | 0.180 |
Why?
|
Selective Estrogen Receptor Modulators | 4 | 2022 | 145 | 0.170 |
Why?
|
Proteogenomics | 1 | 2020 | 87 | 0.170 |
Why?
|
Thiophenes | 1 | 2020 | 148 | 0.170 |
Why?
|
Drug Synergism | 2 | 2016 | 1313 | 0.170 |
Why?
|
SOXB1 Transcription Factors | 1 | 2019 | 123 | 0.170 |
Why?
|
Integrin alpha6 | 1 | 2018 | 17 | 0.170 |
Why?
|
src-Family Kinases | 4 | 2020 | 478 | 0.170 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 470 | 0.170 |
Why?
|
Carcinoma, Lobular | 1 | 2022 | 611 | 0.160 |
Why?
|
Keratins | 2 | 2019 | 330 | 0.160 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2020 | 209 | 0.160 |
Why?
|
Promoter Regions, Genetic | 5 | 2019 | 3101 | 0.160 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2018 | 85 | 0.150 |
Why?
|
Bone and Bones | 1 | 2021 | 619 | 0.150 |
Why?
|
Flavonoids | 1 | 2018 | 188 | 0.150 |
Why?
|
Phenotype | 9 | 2016 | 6295 | 0.150 |
Why?
|
Lasers | 2 | 2014 | 198 | 0.150 |
Why?
|
Survival Analysis | 4 | 2020 | 9180 | 0.150 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 3230 | 0.150 |
Why?
|
Trans-Activators | 1 | 2003 | 1555 | 0.140 |
Why?
|
SOX9 Transcription Factor | 1 | 2017 | 170 | 0.140 |
Why?
|
Cell Survival | 6 | 2021 | 3045 | 0.130 |
Why?
|
Dendritic Cells | 1 | 2022 | 1085 | 0.130 |
Why?
|
Treatment Outcome | 13 | 2023 | 32848 | 0.130 |
Why?
|
Receptor, ErbB-4 | 1 | 2015 | 23 | 0.130 |
Why?
|
Mice, SCID | 3 | 2019 | 1869 | 0.130 |
Why?
|
Drug Liberation | 1 | 2014 | 12 | 0.130 |
Why?
|
Chlorophyll | 1 | 2014 | 14 | 0.130 |
Why?
|
Neoplasm Metastasis | 5 | 2017 | 5112 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 755 | 0.130 |
Why?
|
Nuclear Proteins | 4 | 2020 | 3343 | 0.130 |
Why?
|
NF-kappa B | 1 | 2022 | 1549 | 0.130 |
Why?
|
Photochemistry | 1 | 2014 | 39 | 0.130 |
Why?
|
Ribonucleoside Diphosphate Reductase | 1 | 2014 | 29 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 2488 | 0.120 |
Why?
|
Oxidative Stress | 1 | 2000 | 1129 | 0.120 |
Why?
|
Disease Models, Animal | 8 | 2021 | 7222 | 0.120 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 862 | 0.120 |
Why?
|
MAP Kinase Kinase Kinase 3 | 1 | 2014 | 21 | 0.120 |
Why?
|
Protein Binding | 5 | 2020 | 3438 | 0.120 |
Why?
|
RNA, Messenger | 6 | 2010 | 6150 | 0.120 |
Why?
|
Proteomics | 2 | 2013 | 1380 | 0.120 |
Why?
|
Glutarates | 1 | 2013 | 44 | 0.120 |
Why?
|
Phosphatidylinositols | 1 | 2013 | 60 | 0.120 |
Why?
|
Middle Aged | 15 | 2020 | 86204 | 0.120 |
Why?
|
Acneiform Eruptions | 1 | 2013 | 7 | 0.120 |
Why?
|
Doxycycline | 1 | 2014 | 178 | 0.120 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2018 | 479 | 0.120 |
Why?
|
Nanotechnology | 1 | 2014 | 137 | 0.120 |
Why?
|
Mitochondrial Proteins | 2 | 2013 | 369 | 0.110 |
Why?
|
Genomic Instability | 1 | 2016 | 519 | 0.110 |
Why?
|
Mice, Inbred NOD | 2 | 2013 | 905 | 0.110 |
Why?
|
Mammary Neoplasms, Animal | 2 | 2005 | 221 | 0.110 |
Why?
|
Nuclear Receptor Coactivator 3 | 3 | 2010 | 383 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2013 | 96 | 0.110 |
Why?
|
Genes, myc | 2 | 2011 | 358 | 0.110 |
Why?
|
Liposomes | 1 | 2014 | 684 | 0.110 |
Why?
|
Cytokines | 1 | 2022 | 2809 | 0.110 |
Why?
|
Random Allocation | 1 | 2014 | 703 | 0.110 |
Why?
|
CD24 Antigen | 1 | 2012 | 85 | 0.110 |
Why?
|
Metal Nanoparticles | 1 | 2014 | 164 | 0.110 |
Why?
|
Heat-Shock Proteins | 1 | 2013 | 311 | 0.100 |
Why?
|
Cell Membrane | 2 | 2013 | 850 | 0.100 |
Why?
|
Mice, Inbred BALB C | 3 | 2019 | 2314 | 0.100 |
Why?
|
Mammary Glands, Human | 2 | 2010 | 184 | 0.100 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2011 | 50 | 0.100 |
Why?
|
Neoplasm Staging | 4 | 2020 | 13658 | 0.100 |
Why?
|
Cytoplasm | 2 | 2011 | 652 | 0.100 |
Why?
|
Hyaluronan Receptors | 1 | 2012 | 249 | 0.100 |
Why?
|
Cell Cycle | 5 | 2021 | 2084 | 0.100 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 2010 | 42 | 0.100 |
Why?
|
Drug Eruptions | 1 | 2013 | 256 | 0.100 |
Why?
|
Eukaryotic Initiation Factor-3 | 1 | 2010 | 15 | 0.100 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2011 | 111 | 0.100 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2014 | 461 | 0.100 |
Why?
|
Aged | 13 | 2020 | 70117 | 0.100 |
Why?
|
Cell Differentiation | 1 | 2022 | 4078 | 0.100 |
Why?
|
Antigens, Viral, Tumor | 1 | 2010 | 47 | 0.100 |
Why?
|
Polyomavirus | 1 | 2010 | 30 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2010 | 259 | 0.100 |
Why?
|
Down-Regulation | 5 | 2021 | 2074 | 0.090 |
Why?
|
Gene Rearrangement | 1 | 2014 | 783 | 0.090 |
Why?
|
Lentivirus | 1 | 2011 | 169 | 0.090 |
Why?
|
Genetic Techniques | 1 | 2011 | 130 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 280 | 0.090 |
Why?
|
Adult | 13 | 2020 | 77950 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 980 | 0.090 |
Why?
|
Ovariectomy | 2 | 2008 | 330 | 0.090 |
Why?
|
Tumor Burden | 2 | 2014 | 1987 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2010 | 630 | 0.090 |
Why?
|
Hyperthermia, Induced | 1 | 2014 | 510 | 0.090 |
Why?
|
Genomics | 1 | 2020 | 2738 | 0.090 |
Why?
|
MAP Kinase Kinase 5 | 1 | 2008 | 9 | 0.090 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 2283 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 2 | 2008 | 347 | 0.080 |
Why?
|
Models, Biological | 3 | 2008 | 3254 | 0.080 |
Why?
|
Heparin-binding EGF-like Growth Factor | 1 | 2008 | 21 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2008 | 84 | 0.080 |
Why?
|
Endocrine System | 1 | 2008 | 36 | 0.080 |
Why?
|
Antibodies | 1 | 2011 | 838 | 0.080 |
Why?
|
Protein Processing, Post-Translational | 2 | 2011 | 803 | 0.080 |
Why?
|
Indium Radioisotopes | 1 | 2007 | 65 | 0.080 |
Why?
|
Immunohistochemistry | 5 | 2015 | 7548 | 0.080 |
Why?
|
Carcinogenesis | 3 | 2021 | 1026 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 3 | 2011 | 1823 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 1538 | 0.080 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2010 | 589 | 0.080 |
Why?
|
Cell Division | 3 | 2007 | 2489 | 0.080 |
Why?
|
Follow-Up Studies | 2 | 2019 | 14889 | 0.080 |
Why?
|
Gene Silencing | 3 | 2016 | 837 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3639 | 0.070 |
Why?
|
Mesoderm | 1 | 2008 | 404 | 0.070 |
Why?
|
Immunoconjugates | 1 | 2010 | 279 | 0.070 |
Why?
|
Receptors, CXCR4 | 1 | 2008 | 269 | 0.070 |
Why?
|
Protein Biosynthesis | 1 | 2010 | 889 | 0.070 |
Why?
|
Organometallic Compounds | 1 | 2007 | 191 | 0.070 |
Why?
|
Receptors, Somatotropin | 1 | 2006 | 17 | 0.070 |
Why?
|
Epithelium | 1 | 2008 | 720 | 0.070 |
Why?
|
Nanoparticles | 1 | 2010 | 554 | 0.070 |
Why?
|
Human Growth Hormone | 1 | 2006 | 82 | 0.070 |
Why?
|
Polyamines | 1 | 2005 | 75 | 0.070 |
Why?
|
Laser Therapy | 1 | 2010 | 411 | 0.070 |
Why?
|
Genetic Vectors | 1 | 2011 | 1694 | 0.070 |
Why?
|
Triazoles | 3 | 2015 | 617 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2015 | 1756 | 0.060 |
Why?
|
Paclitaxel | 1 | 2012 | 1996 | 0.060 |
Why?
|
Transfection | 4 | 2013 | 2944 | 0.060 |
Why?
|
Gene Dosage | 1 | 2008 | 829 | 0.060 |
Why?
|
Cell Separation | 2 | 2019 | 612 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2020 | 6009 | 0.060 |
Why?
|
Diagnostic Imaging | 2 | 2011 | 1162 | 0.060 |
Why?
|
Silicon Dioxide | 2 | 2014 | 50 | 0.060 |
Why?
|
Particle Size | 2 | 2014 | 182 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 1331 | 0.060 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 334 | 0.060 |
Why?
|
Protein Kinase C | 1 | 2005 | 396 | 0.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 301 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2020 | 665 | 0.060 |
Why?
|
Nuclear Receptor Coactivator 1 | 1 | 2003 | 236 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 2265 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 1265 | 0.050 |
Why?
|
Acetyltransferases | 1 | 2003 | 143 | 0.050 |
Why?
|
Forecasting | 1 | 2005 | 694 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 1301 | 0.050 |
Why?
|
Receptors, Retinoic Acid | 1 | 2003 | 365 | 0.050 |
Why?
|
Resting Phase, Cell Cycle | 1 | 2021 | 35 | 0.050 |
Why?
|
Tetrahydronaphthalenes | 1 | 2022 | 116 | 0.050 |
Why?
|
Neoplasms | 3 | 2014 | 15193 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2003 | 503 | 0.050 |
Why?
|
Gap Junctions | 1 | 2021 | 43 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2021 | 86 | 0.050 |
Why?
|
Neoplasm Micrometastasis | 1 | 2021 | 49 | 0.050 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 2000 | 118 | 0.050 |
Why?
|
Metabolome | 2 | 2014 | 344 | 0.050 |
Why?
|
Tissue Array Analysis | 2 | 2014 | 760 | 0.050 |
Why?
|
Computational Biology | 2 | 2020 | 1271 | 0.050 |
Why?
|
DNA Methylation | 3 | 2017 | 2669 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2019 | 29902 | 0.050 |
Why?
|
Pentose Phosphate Pathway | 1 | 2000 | 69 | 0.050 |
Why?
|
Gene Ontology | 1 | 2020 | 80 | 0.050 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 615 | 0.050 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2021 | 287 | 0.050 |
Why?
|
G1 Phase | 1 | 2021 | 285 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 3719 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2000 | 166 | 0.050 |
Why?
|
Lipid Peroxidation | 1 | 2000 | 157 | 0.050 |
Why?
|
Cadherins | 1 | 2003 | 660 | 0.050 |
Why?
|
Cell Cycle Proteins | 3 | 2014 | 2045 | 0.050 |
Why?
|
Molecular Conformation | 1 | 2020 | 171 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 5539 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 2000 | 266 | 0.040 |
Why?
|
Cell Cycle Checkpoints | 1 | 2021 | 278 | 0.040 |
Why?
|
Molecular Docking Simulation | 1 | 2020 | 144 | 0.040 |
Why?
|
Gonadal Steroid Hormones | 1 | 2020 | 110 | 0.040 |
Why?
|
Cyclopentanes | 1 | 2019 | 40 | 0.040 |
Why?
|
Glutathione Transferase | 1 | 2000 | 359 | 0.040 |
Why?
|
Nitriles | 2 | 2015 | 906 | 0.040 |
Why?
|
Osteogenesis | 1 | 2021 | 271 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2019 | 11538 | 0.040 |
Why?
|
Biopsy, Large-Core Needle | 1 | 2020 | 134 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2021 | 694 | 0.040 |
Why?
|
Molecular Structure | 1 | 2020 | 515 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2021 | 798 | 0.040 |
Why?
|
Acetylation | 1 | 2020 | 508 | 0.040 |
Why?
|
Leukocyte Common Antigens | 1 | 2019 | 188 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2015 | 4988 | 0.040 |
Why?
|
Oncogene Protein v-akt | 1 | 2018 | 101 | 0.040 |
Why?
|
Protein Isoforms | 3 | 2008 | 842 | 0.040 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 265 | 0.040 |
Why?
|
Cell Communication | 1 | 2021 | 509 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2020 | 931 | 0.040 |
Why?
|
Cell Line | 3 | 2011 | 5114 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 447 | 0.040 |
Why?
|
Oncogene Addiction | 1 | 2017 | 4 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 2 | 2011 | 1062 | 0.040 |
Why?
|
Drug Discovery | 1 | 2020 | 324 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 4938 | 0.040 |
Why?
|
Enzyme Activation | 2 | 2010 | 1764 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2019 | 5710 | 0.040 |
Why?
|
Ubiquitination | 1 | 2019 | 575 | 0.040 |
Why?
|
Dasatinib | 1 | 2020 | 862 | 0.040 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 3981 | 0.040 |
Why?
|
G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 76 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2010 | 4143 | 0.040 |
Why?
|
Cell Movement | 2 | 2014 | 2466 | 0.040 |
Why?
|
Epithelial Cells | 2 | 2014 | 1818 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2008 | 2326 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2020 | 1070 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2014 | 3033 | 0.030 |
Why?
|
Ligands | 1 | 2018 | 995 | 0.030 |
Why?
|
Microscopy, Confocal | 2 | 2010 | 663 | 0.030 |
Why?
|
Disease-Free Survival | 3 | 2015 | 10001 | 0.030 |
Why?
|
Fluoresceins | 1 | 2014 | 73 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 460 | 0.030 |
Why?
|
DNA, Complementary | 2 | 2011 | 869 | 0.030 |
Why?
|
Lasers, Semiconductor | 1 | 2014 | 14 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6207 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2018 | 428 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 3022 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 10035 | 0.030 |
Why?
|
Transducers | 1 | 2014 | 59 | 0.030 |
Why?
|
Photochemotherapy | 1 | 2014 | 96 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 2014 | 148 | 0.030 |
Why?
|
Nanomedicine | 1 | 2014 | 54 | 0.030 |
Why?
|
Surface Properties | 1 | 2014 | 180 | 0.030 |
Why?
|
Materials Testing | 1 | 2014 | 116 | 0.030 |
Why?
|
MAP Kinase Signaling System | 2 | 2011 | 848 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2003 | 4892 | 0.030 |
Why?
|
Drug Design | 1 | 2016 | 375 | 0.030 |
Why?
|
Models, Molecular | 1 | 2019 | 1732 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2014 | 1439 | 0.030 |
Why?
|
Alcohol Oxidoreductases | 1 | 2013 | 45 | 0.030 |
Why?
|
Light | 1 | 2014 | 245 | 0.030 |
Why?
|
Time Factors | 3 | 2015 | 12926 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2014 | 250 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2014 | 249 | 0.030 |
Why?
|
Solubility | 1 | 2013 | 242 | 0.030 |
Why?
|
Immunoblotting | 1 | 2015 | 886 | 0.030 |
Why?
|
Azepines | 1 | 2014 | 124 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2019 | 1620 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2014 | 573 | 0.030 |
Why?
|
Remission Induction | 1 | 2020 | 3569 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 3472 | 0.030 |
Why?
|
Culture Media, Serum-Free | 2 | 2003 | 74 | 0.030 |
Why?
|
Nuclear Receptor Co-Repressor 1 | 2 | 2003 | 71 | 0.030 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 205 | 0.030 |
Why?
|
Pilot Projects | 1 | 2020 | 2803 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
Optics and Photonics | 1 | 2014 | 146 | 0.030 |
Why?
|
Epigenomics | 1 | 2014 | 266 | 0.030 |
Why?
|
Proteolysis | 1 | 2014 | 370 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2014 | 666 | 0.030 |
Why?
|
fas Receptor | 1 | 2013 | 185 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2013 | 4844 | 0.030 |
Why?
|
Glutamine | 1 | 2013 | 299 | 0.030 |
Why?
|
Spindle Apparatus | 1 | 2011 | 93 | 0.030 |
Why?
|
Etoposide | 1 | 2014 | 870 | 0.030 |
Why?
|
Plasmids | 1 | 2013 | 837 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2014 | 702 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2017 | 973 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2014 | 1618 | 0.020 |
Why?
|
Foreskin | 1 | 2010 | 8 | 0.020 |
Why?
|
Sumoylation | 1 | 2011 | 84 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 2483 | 0.020 |
Why?
|
Luminescence | 1 | 2011 | 44 | 0.020 |
Why?
|
Polyribosomes | 1 | 2010 | 34 | 0.020 |
Why?
|
Wnt Signaling Pathway | 1 | 2013 | 430 | 0.020 |
Why?
|
Electromagnetic Fields | 1 | 2010 | 50 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 651 | 0.020 |
Why?
|
F-Box-WD Repeat-Containing Protein 7 | 1 | 2010 | 83 | 0.020 |
Why?
|
Sphingosine | 1 | 2010 | 55 | 0.020 |
Why?
|
Metabolomics | 1 | 2014 | 478 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2010 | 260 | 0.020 |
Why?
|
Fluorescence | 1 | 2010 | 195 | 0.020 |
Why?
|
Breast | 1 | 2017 | 1344 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 543 | 0.020 |
Why?
|
Placebos | 1 | 2011 | 437 | 0.020 |
Why?
|
Ribosomes | 1 | 2010 | 147 | 0.020 |
Why?
|
p21-Activated Kinases | 1 | 2010 | 122 | 0.020 |
Why?
|
Frozen Sections | 1 | 2010 | 105 | 0.020 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2010 | 159 | 0.020 |
Why?
|
Dideoxynucleosides | 1 | 2009 | 19 | 0.020 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2010 | 173 | 0.020 |
Why?
|
Lysophospholipids | 1 | 2010 | 147 | 0.020 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2013 | 480 | 0.020 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 129 | 0.020 |
Why?
|
Fluorouracil | 1 | 2014 | 1944 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1165 | 0.020 |
Why?
|
Mitosis | 1 | 2011 | 615 | 0.020 |
Why?
|
S-Phase Kinase-Associated Proteins | 1 | 2008 | 51 | 0.020 |
Why?
|
Fluorine Radioisotopes | 1 | 2009 | 133 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 2008 | 231 | 0.020 |
Why?
|
Disease Progression | 2 | 2013 | 6682 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 212 | 0.020 |
Why?
|
Cellular Senescence | 1 | 2010 | 382 | 0.020 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2576 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2014 | 984 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2232 | 0.020 |
Why?
|
DNA Damage | 1 | 2016 | 1954 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2013 | 1555 | 0.020 |
Why?
|
Genome, Human | 1 | 2016 | 1869 | 0.020 |
Why?
|
Cell Death | 1 | 2010 | 671 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 342 | 0.020 |
Why?
|
Mammary Glands, Animal | 1 | 2011 | 533 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 1648 | 0.020 |
Why?
|
Taxoids | 1 | 2010 | 967 | 0.020 |
Why?
|
Pyrimidines | 1 | 2019 | 3518 | 0.020 |
Why?
|
Histones | 1 | 2014 | 1466 | 0.020 |
Why?
|
Mitochondria | 1 | 2013 | 1282 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 3005 | 0.020 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 305 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2008 | 368 | 0.020 |
Why?
|
Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2005 | 13 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2008 | 576 | 0.020 |
Why?
|
Dendrimers | 1 | 2005 | 8 | 0.020 |
Why?
|
Shc Signaling Adaptor Proteins | 1 | 2005 | 26 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12221 | 0.020 |
Why?
|
Rhodamines | 1 | 2005 | 49 | 0.020 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 598 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2005 | 300 | 0.020 |
Why?
|
Acetophenones | 1 | 2005 | 19 | 0.020 |
Why?
|
Mitogens | 1 | 2005 | 75 | 0.020 |
Why?
|
Benzopyrans | 1 | 2005 | 41 | 0.020 |
Why?
|
Protein Kinase C-delta | 1 | 2005 | 42 | 0.020 |
Why?
|
Wnt1 Protein | 1 | 2005 | 103 | 0.020 |
Why?
|
Algorithms | 1 | 2016 | 3890 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2010 | 854 | 0.020 |
Why?
|
Logistic Models | 1 | 2012 | 3441 | 0.020 |
Why?
|
Prospective Studies | 2 | 2013 | 12873 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2012 | 4298 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2008 | 1064 | 0.020 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2005 | 243 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2005 | 756 | 0.010 |
Why?
|
Biomarkers | 1 | 2015 | 5047 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 1226 | 0.010 |
Why?
|
Glucose | 1 | 2009 | 1248 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2003 | 394 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2005 | 397 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2003 | 334 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2005 | 554 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 769 | 0.010 |
Why?
|
Genes, Dominant | 1 | 2003 | 331 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 1382 | 0.010 |
Why?
|
Genome | 1 | 2005 | 672 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 21445 | 0.010 |
Why?
|
Genes, p53 | 1 | 2005 | 1090 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 2173 | 0.010 |
Why?
|
Age Factors | 1 | 2010 | 5377 | 0.010 |
Why?
|
Odds Ratio | 1 | 2005 | 2316 | 0.010 |
Why?
|
Kidney | 1 | 2008 | 2146 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2005 | 1506 | 0.010 |
Why?
|
MicroRNAs | 1 | 2011 | 2947 | 0.010 |
Why?
|
Biopsy | 1 | 2005 | 3443 | 0.010 |
Why?
|
DNA | 1 | 2005 | 2693 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 4053 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 7702 | 0.010 |
Why?
|
Osteosarcoma | 1 | 1999 | 929 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 7551 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2011 | 37905 | 0.010 |
Why?
|
Male | 1 | 2010 | 123000 | 0.000 |
Why?
|